madman
Super Moderator
This panel discussion focuses on the medical management of benign prostatic hyperplasia and lower urinary tract symptoms.
The discussion reviews commonly used therapies, including alpha blockers such as tamsulosin, and highlights alternative options that may reduce side effects such as retrograde ejaculation. The panel emphasizes the importance of patient counseling regarding expected changes in ejaculatory function.
Phosphodiesterase type 5 inhibitors, including tadalafil, are discussed as an option for patients with both lower urinary tract symptoms and erectile dysfunction. Combination therapy strategies are reviewed as part of individualized treatment plans.
5-alpha reductase inhibitors, including finasteride and dutasteride, are highlighted for their role in reducing prostate size and preventing disease progression in patients with larger prostates. The panel discusses the importance of interpreting prostate-specific antigen levels in the context of these medications.'
Additional topics include the role of supplements, non-surgical options such as prostate artery embolization, and practical considerations such as medication access and provider bias.
An audience comment highlights the importance of informing ophthalmologists about the use of alpha blockers due to the risk of intraoperative floppy iris syndrome.'
This discussion provides practical insights into the management of BPH.'
